Skip to main content
Clinical Trials/NL-OMON55091
NL-OMON55091
Recruiting
Not Applicable

Vaccination response to pneumococcal antigen as novel predictor for successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia. - The VaccinSTOP study

Albert Schweitzer Ziekenhuis0 sites57 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Albert Schweitzer Ziekenhuis
Enrollment
57
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Aged 18 years or older
  • \- Written informed consent
  • \- Known baseline data on diagnosis and treatment prior to study entry
  • \- Eligible for TKI discontinuation according to current HOVON guidelines (anno
  • 2018\) on the treatment of CML

Exclusion Criteria

  • \- Previously vaccinated against S. pneumoniae
  • \- Known allergy to any constituent of the pneumococcal vaccine
  • \- Patients using any immunosuppressive medication, excluding inhalation
  • corticosteroids and ointments containing corticosteroids

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Immune response test as new predictor for successful TKI stop in patients with chronic myeloid leukemiaChronic myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10009016Term: Chronic myeloid leukemia in remissionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2020-002850-26-NLAlbert Schweitzer Hospital57
Completed
Phase 4
The antibody response to pneumococcal vaccination in patients with inflammatory bowel disease patients treated with immunosuppressive agentsantibody responseprotection after vaccination1001796910027665
NL-OMON45696Academisch Medisch Centrum178
Recruiting
Not Applicable
De antistof respons na pneumokokkenvaccinatie bij IBD-patiënten die behandeld worden met immunosuppressiva – de PNEUMOREACT studieinflammatory bowel disease (inflammatoire darmziekte)immunosuppressive agents (immunosuppressiva)pneumococcal vaccination (pneumokokkenvaccinatie)vaccine immunogenicity (vaccin immunogeniciteit)
NL-OMON29135Academic Medical Center188
Active, not recruiting
Not Applicable
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly18 years old or older volunteers with general good health
EUCTR2012-003484-22-FIHelsinki University Central Hospital600
Active, not recruiting
Not Applicable
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly
EUCTR2012-003484-22-SEHelsinki University Central Hospital300